by barry101 | Mar 6, 2025 | Press Releases
New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second half of 2025 HOUSTON, March 6, 2025 — Moleculin Biotech, Inc.,...
by barry101 | Mar 3, 2025 | Press Releases
HOUSTON, March 3, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its...
by barry101 | Feb 25, 2025 | Press Releases
HOUSTON, Feb. 25, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it...
by barry101 | Feb 13, 2025 | Press Releases
HOUSTON, Feb. 13, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it...
by barry101 | Feb 13, 2025 | Press Releases
Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) in the first quarter of 2025 HOUSTON, Feb. 13, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the...
by barry101 | Feb 11, 2025 | Press Releases
First of many site approvals, including sites in the US, Europe and the Middle East, expected throughout Q1-Q3 2025 Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) in the first quarter of...
